Skip to main content
Biogen10-Q: Compliance burden

U.S. Administration Imposes 100% Tariff on Patented Pharmaceuticals and Biologics Under Section 232

Source: Autobound Signal API · 74 signals tracked for Biogen · updated

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.

What happened

Following a national security investigation under Section 232, the U.S. Administration issued a Proclamation imposing a 100% tariff on imports of patented pharmaceuticals, biologics, and associated ingredients effective July 31 and September 29, 2026. This creates significant supply chain and trade compliance adaptation requirements across biopharma manufacturers.

Source

SEC EDGARJul 29, 2026

Quarterly report (Form 10-Q)

Biogen 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

In April 2026 after the investigation concluded, the U.S. Administration issued a Proclamation imposing a 100% tariff on imports of patented pharmaceuticals, biologics and associated ingredients, subject to certain exemptions and reduced rates. The Proclamation tariffs are effective for certain categories on July 31, 2026, and others on September 29, 2026.

sec.gov/Archives/edgar/data/875045/000087504526000075/biib-20260630.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Compliance burden

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Jul 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
100% (tariff on imports of patented pharmaceuticals, biologics and associated ingredients)

Details

CIK
875045
Accession number
0000875045-26-000075
Timeframe
Current year
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
GRC tools needed
Signal category
Risk

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
70%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every 10-Q signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/345c5d2d-7f36-4f25-a128-5ca922f949b6 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "345c5d2d-7f36-4f25-a128-5ca922f949b6",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-11-09T06:30:46.076+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "detail": "Following a national security investigation under Section 232, the U.S. Administration issued a Proclamation imposing a 100% tariff on imports of patented pharmaceuticals, biologics, and associated ingredients effective July 31 and September 29, 2026. This creates significant supply chain and trade compliance adaptation requirements across biopharma manufacturers.",
    "metrics": {
      "pct": 1,
      "timeframe": "current_year",
      "pct_context": "tariff on imports of patented pharmaceuticals, biologics and associated ingredients"
    },
    "quarter": "Q2",
    "summary": "U.S. Administration Imposes 100% Tariff on Patented Pharmaceuticals and Biologics Under Section 232",
    "excerpts": "In April 2026 after the investigation concluded, the U.S. Administration issued a Proclamation imposing a 100% tariff on imports of patented pharmaceuticals, biologics and associated ingredients, subject to certain exemptions and reduced rates. The Proclamation tariffs are effective for certain categories on July 31, 2026, and others on September 29, 2026.",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000075/biib-20260630.htm",
    "filing_date": "2026-07-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.